These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26609565)

  • 1. The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.
    Tarnowski M; Paradowska-Gorycka A; Dąbrowska-Zamojcin E; Czerewaty M; Słuczanowska-Głąbowska S; Pawlik A
    Expert Opin Drug Metab Toxicol; 2016; 12(1):41-55. PubMed ID: 26609565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics in rheumatoid arthritis.
    Sen D; Paul JR; Ranganathan P
    Methods Mol Biol; 2014; 1175():625-60. PubMed ID: 25150878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis.
    Aluko A; Ranganathan P
    Methods Mol Biol; 2022; 2547():527-567. PubMed ID: 36068476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of therapies in rheumatoid arthritis.
    Ranganathan P
    Drugs Today (Barc); 2005 Dec; 41(12):799-814. PubMed ID: 16474855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
    Taniguchi A; Urano W; Tanaka E; Furihata S; Kamitsuji S; Inoue E; Yamanaka M; Yamanaka H; Kamatani N
    Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate pharmacogenetics in rheumatoid arthritis.
    Brinker RR; Ranganathan P
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of disease-modifying anti-rheumatic drugs.
    Tanaka E; Taniguchi A; Urano W; Yamanaka H; Kamatani N
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):233-47. PubMed ID: 15121042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies toward rheumatoid arthritis therapy; the old and the new.
    Abbasi M; Mousavi MJ; Jamalzehi S; Alimohammadi R; Bezvan MH; Mohammadi H; Aslani S
    J Cell Physiol; 2019 Jul; 234(7):10018-10031. PubMed ID: 30536757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts in the genetic diagnostics of rheumatoid arthritis.
    Nagy ZB; Csanád M; Tóth K; Börzsönyi B; Demendi C; Rigó J; Joó JG
    Expert Rev Mol Diagn; 2010 Jul; 10(5):603-18. PubMed ID: 20629510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics in treatment of rheumatoid arthritis.
    Kooloos WM; Huizinga TW; Guchelaar HJ; Wessels JA
    Curr Pharm Des; 2010; 16(2):164-75. PubMed ID: 20205662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.
    Ranganathan P
    Pharmacogenomics; 2005 Jul; 6(5):481-90. PubMed ID: 16013998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.
    Umićević Mirkov M; Coenen MJ
    Pharmacogenomics; 2013 Mar; 14(4):425-44. PubMed ID: 23438889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?
    Murdaca G; Gulli R; Spanò F; Mandich P; Puppo F
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S7-S10. PubMed ID: 25381983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF treatment in rheumatoid arthritis.
    Geiler J; Buch M; McDermott MF
    Curr Pharm Des; 2011; 17(29):3141-54. PubMed ID: 21864263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When is switching warranted among biologic therapies in rheumatoid arthritis?
    Reynolds A; Koenig AS; Bananis E; Singh A
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):319-33. PubMed ID: 22812556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update.
    Zhu H; Deng FY; Mo XB; Qiu YH; Lei SF
    Pharmacogenomics; 2014 Mar; 15(4):551-66. PubMed ID: 24624921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?
    Ranganathan P; Eisen S; Yokoyama WM; McLeod HL
    Ann Rheum Dis; 2003 Jan; 62(1):4-9. PubMed ID: 12480661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.
    Mok CC; Tsai WC; Chen DY; Wei JC
    Expert Opin Biol Ther; 2016; 16(2):201-11. PubMed ID: 26560845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.